Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Maze Therapeutics, Inc.NASDAQ: MAZE
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $2.21M rose 282.0% year over year, ahead of the +159.9% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -80.7% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +282.0% holds above the trailing-twelve-month pace of +159.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (27K) USD
- Year-over-year change
- +86.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27K) | +86.8% |
| FY2024 | 2024-12-31 | (204K) | -151.1% |
| FY2023 | 2023-12-31 | 399K | +110.6% |
| FY2022 | 2022-12-31 | (3.78M) | — |
Accounts Payables vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +159.9% is the 3rd highest of 6, against a peer median of +151.1%.
- Accounts payables amounts to 8.0% of revenue for MAZE, versus a peer median of 3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.47M USD | +507.1% | -21.1% | 3.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $3.07M USD | +363.6% | +56.4% | 3.2% |
| LTM Sep 2026 | $2.72M USD | +151.1% | — | 0.4% | |
| FY2025 | €2.46M EUR | — | -11.4% | 54.8% | |
| LTM Mar 2026 | $1.8M USD | +126.9% | +33.5% | — | |
| LTM Mar 2026 | $1.61M USD | +159.9% | -80.7% | 8.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $933K USD | -155.1% | -7.4% | 9.0% |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MAZE) | — | +151.1% | -7.4% | 3.3% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.